Citadel Advisors
BLTE

Citadel Advisors’s Belite Bio BLTE Stock Holding History

Citadel Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$320K Sell
2,008
-3,047
-60% -$512K ﹤0.01% 10330
2025
Q4 		$809K Sell
5,055
-5,772
-53% -$684K ﹤0.01% 7893
2025
Q3 		$801K Buy
10,827
+3,371
+45% +$221K ﹤0.01% 8031
2025
Q2 		$430K Buy
7,456
+1,767
+31% +$108K ﹤0.01% 8979
2025
Q1 		$377K Buy
5,689
+478
+9% +$28.8K ﹤0.01% 9090
2024
Q4 		$329K Sell
5,211
-1,249
-19% -$82.3K ﹤0.01% 9459
2024
Q3 		$303K Buy
+6,460
New +$313K ﹤0.01% 9314

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's BLTE Position: Q1 2026 in Review

Citadel Advisors reduced its Belite Bio (BLTE) stake by 60% in Q1 2026, selling an estimated $512K and leaving 2,008 shares worth $320K. The position accounts for ﹤0.01% of the portfolio, ranked #10330.

Citadel Advisors first reported a position in BLTE in Q3 2024 and has held it in 7 quarters since. The position peaked at $809K in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Citadel Advisors held 2,008 shares of Belite Bio worth $320K as of Q1 2026.
  • Citadel Advisors sold 3,047 Belite Bio shares in Q1 2026, an estimated $512K.
  • Belite Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10330 holding.
  • Citadel Advisors first reported a position in Belite Bio in Q3 2024 and has held it in 7 quarters since.
  • Citadel Advisors's Belite Bio position peaked at $809K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.